Business Development

Clinical Development Pipeline

PRODUCT	TYPE	INDICATION(S)	DEVELOPMENT STATUS
Rindopepimut (CDX-110)	Vaccine	Front-line Glioblastoma	Phase 3
Rindopepimut (CDX-110)	Vaccine	Recurrent Glioblastoma	Phase 2
CDX-011*	Antibody-drug conjugate	Breast Cancer	Phase 2b
CDX-1401	Antibody-vaccine	Multiple Solid Tumors	Phase 1/2
CDX-1127	Antibody	Lymphoma/Leukemia and Solid Tumors	Phase 1
CDX-301 (Flt3L)	Protein	Cancer, Autoimmune Disease and Transplant	Phase 1

*CDX-011: glembatumumab vedotin (ADC technology licensed from Seattle Genetics)

Additional Programs

PRODUCT	TYPE	INDICATION(S)	DEVELOPMENT STATUS
CDX-1135 (sCR1, TP-10)	Soluble receptor	Renal Disease	Preclinical
CDX-014	Antibody-drug conjugate / Antibody	Ovarian and Renal Cancers	Preclinical

Celldex is interested in exploring collaborative discussions to leverage our portfolio of therapeutic product candidates, as well as development and commercialization partnerships around our on-going clinical programs. Our objective is to enter into partnerships that will enhance our mutual ability to advance novel science and accelerate the development of truly life-changing therapies for our patients.

Our current portfolio of clinical development candidates will also form the basis for co-development and commercialization partnerships, as Celldex intends to leverage the marketing and distribution capabilities of major pharmaceutical partners for our immunotherapies. Our broad intellectual property portfolio and scientific expertise will enable us to establish meaningful commercial relationships in our core areas of disease management – oncology, infectious disease and auto-immune disorders.

Celldex is currently seeking the following types of business partnerships:

Licensing partner to commercialize rindopepimut (CDX-110) in the markets outside of North America, CDX-011 and/or CDX-1127.
Preclinical R&D relationships using proprietary antigens and/or targets that could form the basis for an APC antibody-antigen targeted therapy.
Preclinical R&D or clinical relationships around the development of therapeutic antibodies, particularly with proprietary disease antigens supplied either by Celldex or from collaborative partners.

To effectively execute our business plan and develop novel products, we strongly believe in the mutual benefits that result from external collaborations with partners. Accordingly, Celldex has established a number of successful corporate, government and academic partnerships.

Our strategy is to demonstrate proof of concept for our products before leveraging their value through partnerships. We are confident that we offer a range of highly-innovative approaches to manipulating the human immune system to improve disease management and clinical outcomes and see exciting partnering opportunities for companies with strong immunotherapy franchises.

The following partnerships have already been established:

	The Ludwig Institute for Cancer Research (LICR) – In October 2006, Celldex entered a multi-year clinical research collaboration focusing on a series of tumor-associated antigens (TAAs) for use in Celldex’s APC Targeting Technology™. These antigens, previously identified and characterized immunologically by LICR, will be added to Celldex’s development programs for a range of cancer types. Three of these antigens (NY-ESO-1, MAGE3, and MelanA) are being studied in non-small cell lung, ovarian, and bladder cancers, as well as melanoma, in an extended series of Phase 1/2 programs conducted by the LICR and its collaborators.
	Medarex (now Bristol-Myers Squibb) – Through our formation from within Medarex in October 2005, Celldex retains the exclusive right to use the Medarex ‘huMAb’ mice for the development of antibody-based immunotherapies (including our core APC Targeting Technology™), as well as the right to enter into ten (10) therapeutic antibody collaborations around novel targets.
	The Rockefeller University – Celldex has licensed intellectual property from Rockefeller to target the DEC-205 family of mannose receptors in human dendritic cells, leveraging discoveries from the laboratories of Professor Ralph Steinman and Michel Nussenzweig. Professors Steinman and Nussenzweig also sit on our Scientific Advisory Board. DEC-205 is a key receptor for certain antigen processing pathways, and having access to this IP greatly enhances our ability to develop highly-targeted immunotherapies. Celldex is also collaborating with Rockefeller to develop CDX-2401, a novel vaccine against HIV, the virus known to cause AIDS. This project is supported through a $14 million grant from the Grand Challenges for Global Health program within the Bill & Melinda Gates Foundation. The project is using the same human antibodies to DEC-205 receptors to selectively initiate robust immune responses against specifically selected HIV antigens.
	GlaxoSmithKline – In 1997, Celldex licensed a rotavirus strain to GlaxoSmithKline that was used in development of Rotarix®. Rotarix® has now been approved worldwide, most recently receiving marketing approval in the United States in 2008, triggering milestone payments to Celldex.
	Vaccine Technologies, Inc. (VTI) – In January 2009, Celldex entered into an agreement with VTI under which VTI was granted a worldwide fee- and royalty-bearing exclusive license to develop and commercialize Celldex's CholeraGarde® and ETEC vaccine programs. The agreement includes upfront license fees, milestone payments and royalties on net sales of licensed products during the term of the agreement.
	Amgen – In March 2009, Celldex entered into an agreement with Amgen in which Celldex acquired exclusive rights to develop and commercialize two immune-stimulatory molecules known as FMS-like tyrosine kinase 3 ligand or Flt3L (now referred to as CDX-301) and CD40 ligand (CD40L). These rights enhance Celldex’s Precision Targeted Immunotherapy Platform.

Partner Contact

Business Development

Clinical Development Pipeline

Additional Programs